Home Health VNA IV Medication Clinical Fact Sheet

V Medication:	Infliximab / Remicade	Risk Level:1			
Лed Class:	Monoclonal Antibody	_			
		Rheumatoid Arthritis, Crohn's Disease,			
	Common Uses:	Psoriatic Arthritis			
	Labs to Monitor:	CBC with Diff			
		Hypersensitivity reaction; monitor BP and Pulse q 30min during infusion; CHF may occur or worsen; flu-like symptoms, serious infections and malignancies may occur; pre-			
	Instructions/Precautions:	meds frequently used; secondary infusion uses 1.2 filter; do not give if active infection			
	First Dose Allowed: Central Line Only: IV Push: Vesicant:	N N N			
	See Procedure Manual:	n/a			
otes:	Only drugs listed as First Dose Allowed may be given in the home as a first dose and are				
	considered for a first dose on a case by case basis by the IV Program Manager				
	The IV Manager and/or Clinical Director must be o	onsulted before a first dose referral is accepted			
isk Levels:	n/a = Routinely given; Clinician must be app 1= IV Program Mgr or Clinical Director ap 2= IV Program Mgr notification; Clinician	proval before referral is accepted			

	Drug			
	Name			
	(generic/t		Common	
High Risk	rade)	Class	Uses	Labs

1 Infliximab , Monoclona Rheumatoi CBC with $\ensuremath{\mathsf{D}}$

Hypersens X 0 0 0 0